The tuberculosis (TB) vaccine MTBVAC is the only live-attenuated ()-based vaccine in clinical development, and it confers superior protection in different animal models compared to the current vaccine, BCG ( bacillus Calmette-Guérin). With the aim of using MTBVAC as a vector for a dual TB-HIV vaccine, we constructed the recombinant MTBVAC.HIVA strain. First, we generated a lysine auxotroph of MTBVAC (MTBVACΔ) by deleting the gene. Then the auxotrophic MTBVACΔ was transformed with the -mycobacterial vector p2auxo.HIVA, harboring the -complementing gene and the HIV-1 clade A immunogen HIVA. This TB-HIV vaccine conferred similar efficacy to the parental strain MTBVAC against challenge in mice. MTBVAC.HIVA was safer than BCG and MTBVAC in severe combined immunodeficiency (SCID) mice, and it was shown to be maintained up to 42 bacterial generations and up to 100 days after inoculation . The MTBVAC.HIVA vaccine, boosted with modified vaccinia virus Ankara (MVA).HIVA, induced HIV-1 and -specific interferon-γ-producing T cell responses and polyfunctional HIV-1-specific CD8+ T cells producing interferon-γ (IFN-γ), tumor necrosis factor alpha (TNF-α), and CD107a in BALB/c mice. Here we describe new tools to develop combined vaccines against TB and HIV with the potential of expansion for other infectious diseases.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6395831 | PMC |
| http://dx.doi.org/10.1016/j.omtm.2019.01.014 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Development, implementation, and evaluation of an innovative clinical trial operations training program for Africa (ClinOps).
BMC Med Educ
January 2025
Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), College of Health Sciences, Addis Ababa University, P.O. Box 9086, Addis Ababa, Ethiopia.
Background: Africa's involvement in clinical trials remains very low. Although the crucial role of training initiatives in building clinical trial capacity in Africa has been documented, current efforts fall short as they lack alignment with local contexts. This study aimed to design, develop, implement, and evaluate an innovative clinical trial operations training program for Africa.
View Article and Find Full Text PDFFeasibility of implementing viral hepatitis services into a correctional service facility in Cape Town, South Africa.
Int J Drug Policy
January 2025
Division of Hepatology, Department of Medicine, Faculty of Health Sciences, University of Cape Town and Groote Schuur Hospital, Main Road, Observatory, Cape Town, South Africa. Electronic address:
Background: Hepatitis B virus (HBV) and hepatitis C virus (HCV) are estimated to be of the most prevalent infectious diseases in correctional settings worldwide. However, viral hepatitis services have not been routinely integrated into South African correctional facilities. We aimed to assess prevalence of HBV infection and HCV infection among people accessing HIV services and assess the feasibility of viral hepatitis service integration in a South African correctional centre.
View Article and Find Full Text PDFInfection Screening and Vaccination of Adult and Pediatric Patients with Autoimmune Inflammatory Rheumatic Diseases: An Emirati Delphi Consensus.
Curr Rheumatol Rev
January 2025
Department of Rheumatology, Dubai Hospital, Dubai Academic Health Corporation, Dubai, United Arab Emirate.
Introduction: Patients with autoimmune and inflammatory rheumatic diseases (AIIRD) have an increased susceptibility to infections due to their compromised immune systems and the use of immunosuppressive therapies. Infections are a leading cause of morbidity and mortality in these patients, emphasizing the need for strategies such as infection control and vaccination to prevent avoidable harm to both patients and healthcare workers. This study aims to provide expert consensus on infection screening and vaccination guidelines for AIIRD patients.
View Article and Find Full Text PDFUpdate of diagnostic methods in tuberculosis (TB).
Rev Argent Microbiol
January 2025
Servicio de Microbiología, Universidad Católica de Córdoba, Clínica Universitaria Reina Fabiola, Córdoba, Argentina. Electronic address:
The WHO aims to reduce the number of deaths from TB by 95% and decrease its incidence rate by 90% between 2015 and 2035. The recommended rapid diagnostic tests are accurate and cost-effective, allow for a prompt start to treatment, and influence other outcomes that are important to the patient. To detect latent infection, the tuberculin skin test and interferon γ release (IGRA) tests are used.
View Article and Find Full Text PDFPET/CT guided tuberculosis treatment shortening: a randomized trial.
medRxiv
October 2024
Tuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, Division of Intramural Research, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, USA.
Six months of chemotherapy using current agents is standard of care for pulmonary, drug-sensitive tuberculosis (TB), even though some are believed to be cured more rapidly and others require longer therapy. Understanding what factors determine the length of treatment required for durable cure in individual patients would allow individualization of treatment durations, provide better clinical tools to determine the of appropriate duration of new regimens, as well as reduce the cost of large Phase III studies to determine the optimal combinations to use in TB control programs. We conducted a randomized clinical trial in South Africa and China that recruited 704 participants with newly diagnosed, drug-sensitive pulmonary tuberculosis and stratified them based on radiographic disease characteristics as assessed by FDG PET/CT scan readers.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!